Silihan lan utang jangka dawa perusahaan Biohaven Pharmaceutical (BHVN)

Biohaven Ltd. (BHVN) specializes in developing treatments for neurodegenerative pathologies and migraines, leveraging patient commitment. However, R&D expenses coupled with a revenue deficit are leading to the depletion of reserves and a search for borrowed funds, as captured by the metric at 0.28. Simultaneously, the company is implementing eco-standards and bioethics. This chart of stock quotes clearly illustrates the issuer's current financial dynamics.

Long-term debt records the total volume of credit obligations with maturities exceeding one year, allowing for an assessment of financial stability and the cost of strategic capital. By analyzing the current level of the business's long-term borrowed capital, an investor can evaluate the risks of Biohaven Ltd. (BHVN), whose massive expenditures on the final stages of clinical trials require significant external financing until the drugs are commercialized.